While this system does provide incentives for certain kinds of research by making innovation profitable, it allows drug companies to drive up prices, and the incentives do not necessarily correspond to social returns. In the health-care sector, it may be more profitable to devote research to a “me-too” drug than to the development of a treatment that really makes a difference.